Holen Sie sich die Stockscreener-App
72.28
1.19%
-0.87
Handel nachbörslich:
72.99
0.71
+0.98%
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio Pharma, Inc. (BBIO) Stock forecasts - Yahoo Finance UK
BBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - Moomoo
BridgeBio to present LGMD2I/R9 trial data at MDA conference By Investing.com - Investing.com India
Viking funds hold 6.1% of BridgeBio Pharma (NASDAQ: BBIO) - Stock Titan
BridgeBio to present LGMD2I/R9 trial data at MDA conference - Investing.com
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Offer Insights on Healthcare Companies: Danaher (DHR), 60 Degrees Pharmaceuticals, Inc. (SXTP) and BridgeBio Pharma (BBIO) - The Globe and Mail
Bond Watch: Is BridgeBio Pharma Inc stock a value trapEarnings Trend Report & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Allspring Global Investments Holdings LLC Has $77.78 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - marketbeat.com
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
Sentiment Review: Will BridgeBio Pharma Inc benefit from green energy policies2026 Biggest Moves & Low Volatility Stock Recommendations - baoquankhu1.vn
Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here’s Why - Insider Monkey
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Bridgebio asks FDA to approve potential 1st treatment for LGMD2i - Muscular Dystrophy News
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $111 - Moomoo
BridgeBio's rare-disease pipeline sparks growth buzz - MSN
INVESCO Small Cap Equity Fund's BridgeBio Pharma Inc(BBIO) Holding History - GuruFocus
Assenagon Asset Management S.A. Decreases Stock Position in BridgeBio Pharma, Inc. $BBIO - marketbeat.com
BridgeBio submits NDA for oral BBP-418 to treat LGMD2I/R9 - Investing.com Australia
BridgeBio Submits NDA for BBP-418 in LGMD2I/R9, Potentially the First Approved Therapy for Any Form of Limb-Girdle Muscular Dystrophy - neurologylive.com
BridgeBio Files NDA for LGMD2I/R9 Oral Therapy - TipRanks
BridgeBio (BBIO) Shares Promising Long-Term Acoramidis Data at A - GuruFocus
BridgeBio (BBIO) Submits Application for New Muscular Dystrophy Treatment - GuruFocus
BridgeBio (NASDAQ: BBIO) files NDA for first potential LGMD2I/R9 treatment - Stock Titan
BridgeBio reports sustained mortality benefits for acoramidis at 54 months By Investing.com - Investing.com Canada
BridgeBio Pharma Announces Sustained Clinical Benefits of Acoramidis in Long-Term ATTRibute-CM Trial - Quiver Quantitative
BridgeBio Pharma, Inc. Presents Long-Term Efficacy and Safety Data from the ATTRibute-CM Open-Label Extension Trial - marketscreener.com
Jefferies reiterates Buy on BridgeBio Pharma stock, $100 target By Investing.com - Investing.com Canada
BridgeBio submits NDA to FDA for BBP-418 for individuals living with LGMD2I/R9 - marketscreener.com
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 - manilatimes.net
BridgeBio Pharma stock drops 3.97% as NDA filed with FDA for BBP-418 therapy - Traders Union
5 High Growth Healthcare Stocks to Buy Now - Insider Monkey
BridgeBio Pharma stock price forecast: mixed signals as BBIO retreats 3.97% toward key support - Traders Union
Will New Long-Term ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Narrative? - Yahoo Finance
BridgeBio Pharma (MIL:1BBIO) PB Ratio : (As of Mar. 28, 2026) - GuruFocus
(BBIO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Phase III wins lift shares of Compass, Palvella and Bridgebio in February - BioWorld MedTech
Vanguard disaggregates holdings; reports 0 Bridgebio shares (BBIO) - Stock Titan
Returns Recap: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEAR - baoquankhu1.vn
Market Catalysts: Whats next for BridgeBio Pharma Inc stock2026 Technical Overview & Fast Gaining Stock Reports - baoquankhu1.vn
1BBIO.MI Stock Price, Quote & Chart | BRIDGEBIO PHARMA INC (BIT:1BBIO) - ChartMill
MOODY ALDRICH PARTNERS LLC's BridgeBio Pharma Inc(BBIO) Holding History - GuruFocus
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions - The Manila Times
BridgeBio heart drug lands late-breaking ACC slot with survival data - Stock Titan
Aug Retail: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEARPortfolio Profit Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
BridgeBio Pharma, Inc. (BBIO) Latest Stock News & Headlines - Yahoo Finance
BridgeBio Pharma (BBIO) President and CFO receives 59,041 RSU equity grant - Stock Titan
BridgeBio (BBIO) CAO awarded 14,170 RSUs in new equity grant - Stock Titan
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio (BBIO) CEO Neil Kumar awarded options and 104,313 RSUs - Stock Titan
Mizuho Raises Price Target on BridgeBio Pharma to $106 From $91, Keeps Outperform Rating - marketscreener.com
BridgeBio Pharma launches initiative to define age-specific pathways for FGFR3 testing - Traders Union
Mizuho raises BridgeBio Pharma stock price target on drug strength By Investing.com - Investing.com Canada
Mizuho raises BridgeBio Pharma stock price target on drug strength - Investing.com
Mizuho Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
BBIO: Mizuho Raises Price Target to $106, Maintains 'Outperform' Rating | BBIO Stock News - GuruFocus
Raymond James Maintains BridgeBio Pharma (BBIO) Outperform Recommendation - MSN
BridgeBio outlines transition to cash generation by 2028 with $600M profit target, driven by pipeline advances and Attruby growth - MSN
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):